

IN THE NEW ERA OF UNIVERSAL ADULT HEPATITIS B VACCINATION, PROTECTING YOUR PATIENTS IS AS<sup>1,\*</sup>

# EASY AS 1-2-3


HEPLISAV-B is the first and only adult hepatitis B vaccine that provides series completion with just **2 DOSES IN 1 MONTH**<sup>2,3</sup>

THE CDC ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) VOTED TO RECOMMEND UNIVERSAL HEPATITIS B VACCINATION FOR ALL ADULTS AGED 19-59<sup>1,\*</sup>

## Change is coming...

Second to influenza, hepatitis B is projected to have the highest number of eligible patients to vaccinate—retail pharmacies will play a critical role in administering these vaccines<sup>1,4,†</sup>

HOW MANY ADULTS ARE RECOMMENDED FOR VACCINATION IN 2022?<sup>1,4</sup>



3-dose hepatitis B vaccines can be suboptimal for the retail pharmacy setting when a 2-dose option is available

The 3-dose hepatitis B vaccines can create:

- ! Additional workflow interruptions
- ! Added callbacks & follow-ups
- ! Scheduling challenges

Using a hepatitis B vaccine that requires fewer doses over a shorter period may reduce these complications<sup>5</sup>

\* The CDC ACIP voted to recommend hepatitis B vaccination for all adults aged 19-59. The ACIP also voted to recommend that all adults aged 60 and older with risk factors for hepatitis B infection should be vaccinated. Adults aged 60 and older without known risk factors may receive hepatitis B vaccination.<sup>1</sup>

† Adults eligible for influenza vaccines calculated from population aged 18+ in 2022; adults eligible for shingles vaccines calculated using adults turning 50 years old in 2022, adults aged >50 who are unvaccinated based on CDC coverage rates, and immunocompromised adults aged 19-49; adults eligible for pneumonia vaccines included adults aged 65+ and at-risk adults aged 18-64 excluding smokers, patients with chronic heart disease, and patients who are immunocompromised; adults eligible for hepatitis B vaccines included general population aged ≤59 and at-risk adults aged 19+ calculated based on CDC ACIP assessment, converted to patient numbers using compliance data from Nelson et al.<sup>4</sup>

## INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

NDC#: 43528-0003-05

## IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Please see additional Important Safety Information on next page and [click here](#) for full Prescribing Information.

**HEPLISAV-B**<sup>®</sup>  
Hepatitis B Vaccine (Recombinant), Adjuvanted  
**2 DOSES. 1 MONTH. DONE.<sup>2</sup>**

# VACCINES WITH FEWER DOSES CAN BENEFIT PHARMACIES AND PATIENTS<sup>5,6</sup>

2-dose HEPLISAV-B makes vaccination faster and more efficient<sup>5,6</sup>



Streamlined operational workflow  
Faster, easier option for patients  
Higher rates of patient protection

## IN A RECENT SURVEY\*



**MOST ADULTS PREFERRED  
A 2-DOSE, 1-MONTH VACCINE  
OVER A 3-DOSE, 6-MONTH VACCINE<sup>4</sup>**

## IN A REAL-WORLD STUDY

a large healthcare system evaluated the impact of simply switching to HEPLISAV-B and found that

**2X MORE**  
ADULTS COMPLETED THE  
**HEPLISAV-B SERIES**  
THAN THOSE STARTING WITH ENGERIX-B<sup>7</sup>

**EFFICIENT ACCESS: HEPLISAV-B is available to order through distributors and has coverage parity with other adult hepatitis B vaccines**

\* In a survey of 1002 adults in the United States who use a pharmacy and are likely to receive a vaccination at a pharmacy, 71.26% (n=714) preferred 2 doses over 1 month, 19.26% (n=193) had no preference, and 9.48% (n=95) preferred 3 doses over 6 months.<sup>4</sup>

Learn more at [HEPLISAVB.com/pharmacist](https://HEPLISAVB.com/pharmacist)

## IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please [click here](#) for full Prescribing Information.

**REFERENCES:** 1. Landmark vote by CDC's Advisory Committee on Immunization Practices (ACIP) to recommend universal hepatitis B vaccination. Hepatitis B Foundation. November 4, 2021. Accessed February 4, 2022. <https://hepb.org/news-and-events/news-2/the-cdcs-advisory-committee-on-immunization-practices-acip-voted-to-recommend-universal-hepatitis-b-vaccination> 2. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 3. Freedman M, Kroger A, Hunter P, Ault KA. Recommended adult immunization schedule, United States, 2020. *Ann Intern Med.* 2020;172(5):337-347. doi:10.7326/M20-0046 4. Data on file. Dynavax Technologies Corporation; 2022. 5. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. *Am J Public Health.* 2009;99(suppl 2):S389-397. doi:10.2105/AJPH.2008.151332 6. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD. 7. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. *JAMA Netw Open.* 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577

**DYNAVAX**

© 2022 Dynavax Technologies Corporation. All rights reserved.  
February 2022 US-22-00-00043

NDC#: 43528-0003-05

**HEPLISAV-B®**  
Hepatitis B Vaccine (Recombinant), Adjuvanted  
**2 DOSES. 1 MONTH. DONE.²**